Ibalizumab Biosimilar

REQUEST MORE INFO
Catalogue No: abx831129
Price: US$435.00
(Size: 100 µg)

Orders to United States ship from United States

Click on the image to see the image legend

Available Options

* Size:




Add to Cart Buy It Now GET A QUOTE

Documents

Datasheet SDS
Ibalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD4 D3 domain, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8, 5.

Target CD4 D3 domain
Research Area Humanized Monoclonal Antibodies, Biosimilars
Clonality Monoclonal
Reactivity Human
Expression Recombinant
Tested Applications ELISA
Host Human
Recommended dilutions Optimal dilutions/concentrations should be determined by the end user.
Conjugation Unconjugated
Isotype IgG4 Kappa
Form Liquid
Purity > 95%
Purification Purified from cell culture supernatants by Protein A/G chromatography.
Storage Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life 12 months.
Buffer 0.01 M PBS, pH 7.4.
CAS Number 680188-33-4
Concentration Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability Shipped within 5-10 working days.
Note THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Research Articles on CD4 D3 domain


Write a review

Tags:
(Click to show)